International Clinical Trial: A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma

Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127842) titled 'A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma' on July 8.

Study Type: Interventional study

Study Design: Cross-over

Primary Sponsor: Shanghai General Hospital

Condition: Asthma

Intervention: B Group :Sequence 1: Treatment Period 1 (BDA MDI HFO) ? Treatment Period 2 (BDA MDI HFA) ? Treatment Period 3 (Placebo MDI HFA) Sequence 2: Treatment Period 1 (BDA MDI HFO) ? Treatment Period 2...